Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated:  6/3/2014
Maine Medical Center
696
mi
from 43215
Scarborough, ME
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated: 6/3/2014
Maine Medical Center
696
mi
from 43215
Scarborough, ME
Click here to add this to my saved trials
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated:  6/3/2014
University of Maryland School of Medicine
343
mi
from 43215
Baltimore, MD
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated: 6/3/2014
University of Maryland School of Medicine
343
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated:  6/3/2014
Massachusetts General Hospital
643
mi
from 43215
Boston, MA
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated: 6/3/2014
Massachusetts General Hospital
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated:  6/3/2014
Umass Memorial Medical Center
604
mi
from 43215
Worcester, MA
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated: 6/3/2014
Umass Memorial Medical Center
604
mi
from 43215
Worcester, MA
Click here to add this to my saved trials
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated:  6/3/2014
Cleveland Clinic
129
mi
from 43215
Cleveland, OH
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated: 6/3/2014
Cleveland Clinic
129
mi
from 43215
Cleveland, OH
Click here to add this to my saved trials
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated:  6/3/2014
The Ohio State University, Wexner Medical Center
1
mi
from 43215
Columbus, OH
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated: 6/3/2014
The Ohio State University, Wexner Medical Center
1
mi
from 43215
Columbus, OH
Click here to add this to my saved trials
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated:  6/3/2014
Oregon Health & Science University Hospital
2027
mi
from 43215
Portland, OR
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated: 6/3/2014
Oregon Health & Science University Hospital
2027
mi
from 43215
Portland, OR
Click here to add this to my saved trials
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated:  6/3/2014
Abington Memorial Hospital
417
mi
from 43215
Abington, PA
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated: 6/3/2014
Abington Memorial Hospital
417
mi
from 43215
Abington, PA
Click here to add this to my saved trials
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated:  6/3/2014
UPMC Presbyterian Hospital
165
mi
from 43215
Pittsburgh, PA
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated: 6/3/2014
UPMC Presbyterian Hospital
165
mi
from 43215
Pittsburgh, PA
Click here to add this to my saved trials
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated:  6/3/2014
Medical University of South Carolina
524
mi
from 43215
Charleston, SC
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated: 6/3/2014
Medical University of South Carolina
524
mi
from 43215
Charleston, SC
Click here to add this to my saved trials
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated:  6/3/2014
University of Utah Healthcare
1513
mi
from 43215
Salt Lake City, UT
Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
A Randomized, Multi-center, Prospective, Double Blind, Two-stage, Adaptive Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Status: Enrolling
Updated: 6/3/2014
University of Utah Healthcare
1513
mi
from 43215
Salt Lake City, UT
Click here to add this to my saved trials
An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury
Randomized, Double-Blind, Placebo Controlled, Phase 2a Trial of ZGN-440 (Subcutaneous Beloranib in Suspension), A Novel Methionine Aminopeptidase 2 Inhibitor, in Obese Subjects With Hypothalamic Injury to Evaluate Weight Reduction and Safety Over 4 Weeks Followed by an Optional 4-Week Open-Label Extension
Status: Enrolling
Updated:  6/3/2014
Childrens Hospitals And Clinics Of Minnesota
617
mi
from 43215
St. Paul, MN
An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury
Randomized, Double-Blind, Placebo Controlled, Phase 2a Trial of ZGN-440 (Subcutaneous Beloranib in Suspension), A Novel Methionine Aminopeptidase 2 Inhibitor, in Obese Subjects With Hypothalamic Injury to Evaluate Weight Reduction and Safety Over 4 Weeks Followed by an Optional 4-Week Open-Label Extension
Status: Enrolling
Updated: 6/3/2014
Childrens Hospitals And Clinics Of Minnesota
617
mi
from 43215
St. Paul, MN
Click here to add this to my saved trials
An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury
Randomized, Double-Blind, Placebo Controlled, Phase 2a Trial of ZGN-440 (Subcutaneous Beloranib in Suspension), A Novel Methionine Aminopeptidase 2 Inhibitor, in Obese Subjects With Hypothalamic Injury to Evaluate Weight Reduction and Safety Over 4 Weeks Followed by an Optional 4-Week Open-Label Extension
Status: Enrolling
Updated:  6/3/2014
Vanderbilt University Medical Center
333
mi
from 43215
Nashville, TN
An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury
Randomized, Double-Blind, Placebo Controlled, Phase 2a Trial of ZGN-440 (Subcutaneous Beloranib in Suspension), A Novel Methionine Aminopeptidase 2 Inhibitor, in Obese Subjects With Hypothalamic Injury to Evaluate Weight Reduction and Safety Over 4 Weeks Followed by an Optional 4-Week Open-Label Extension
Status: Enrolling
Updated: 6/3/2014
Vanderbilt University Medical Center
333
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
Constraint Induced Movement Therapy Summer Camp
Constraint Induced Movement Therapy Summer Camp for Children With Unilateral Cerebral Palsy Ages 3-7
Status: Enrolling
Updated:  6/3/2014
Nationwide Children's Hospital
2
mi
from 43215
Columbus, OH
Constraint Induced Movement Therapy Summer Camp
Constraint Induced Movement Therapy Summer Camp for Children With Unilateral Cerebral Palsy Ages 3-7
Status: Enrolling
Updated: 6/3/2014
Nationwide Children's Hospital
2
mi
from 43215
Columbus, OH
Click here to add this to my saved trials
Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis
Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis
Status: Enrolling
Updated:  6/5/2014
Oregon Health and Science University
2026
mi
from 43215
Portland, OR
Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis
Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis
Status: Enrolling
Updated: 6/5/2014
Oregon Health and Science University
2026
mi
from 43215
Portland, OR
Click here to add this to my saved trials
Hyperbaric Oxygen Treatment to Treat Mild Traumatic Brain Injury (mTBI)/Persistent Post-Concussion Syndrome (PPCS)
Hyperbaric Oxygen Therapy Treatment of Chronic Mild Traumatic Brain Injury (mTBI)/Persistent Post-Concussion Syndrome (PPCS)
Status: Enrolling
Updated:  6/9/2014
Louisiana State University Health Sciences Center- New Orleans
798
mi
from 43215
New Orleans, LA
Hyperbaric Oxygen Treatment to Treat Mild Traumatic Brain Injury (mTBI)/Persistent Post-Concussion Syndrome (PPCS)
Hyperbaric Oxygen Therapy Treatment of Chronic Mild Traumatic Brain Injury (mTBI)/Persistent Post-Concussion Syndrome (PPCS)
Status: Enrolling
Updated: 6/9/2014
Louisiana State University Health Sciences Center- New Orleans
798
mi
from 43215
New Orleans, LA
Click here to add this to my saved trials
Virtual Reality-Based Exercise in Cancer Patients
Virtual Reality-Based Exercise in Cancer Patients With Chemotherapy Induced Peripheral Neuropathy
Status: Enrolling
Updated:  6/16/2014
University of Arizona Cancer Center
1639
mi
from 43215
Tucson, AZ
Virtual Reality-Based Exercise in Cancer Patients
Virtual Reality-Based Exercise in Cancer Patients With Chemotherapy Induced Peripheral Neuropathy
Status: Enrolling
Updated: 6/16/2014
University of Arizona Cancer Center
1639
mi
from 43215
Tucson, AZ
Click here to add this to my saved trials
Pilot Study of Melatonin and Epilepsy
Melatonin and Sleep in Patients With Epilepsy
Status: Enrolling
Updated:  6/17/2014
Cincinnati Children's Hospital Medical Center
97
mi
from 43215
Cincinnati, OH
Pilot Study of Melatonin and Epilepsy
Melatonin and Sleep in Patients With Epilepsy
Status: Enrolling
Updated: 6/17/2014
Cincinnati Children's Hospital Medical Center
97
mi
from 43215
Cincinnati, OH
Click here to add this to my saved trials
Simvastatin in Aneurysmal Subarachnoid Haemorrhage (STASH) a Multicentre Randomised Controlled Clinical Trial
Simvastatin in Aneurysmal Subarachnoid Haemorrhage (STASH) a Multicentre Randomised Controlled Clinical Trial
Status: Enrolling
Updated:  6/24/2014
Dept of Neurological Surgery, University of Florida
711
mi
from 43215
Gainesville, FL
Simvastatin in Aneurysmal Subarachnoid Haemorrhage (STASH) a Multicentre Randomised Controlled Clinical Trial
Simvastatin in Aneurysmal Subarachnoid Haemorrhage (STASH) a Multicentre Randomised Controlled Clinical Trial
Status: Enrolling
Updated: 6/24/2014
Dept of Neurological Surgery, University of Florida
711
mi
from 43215
Gainesville, FL
Click here to add this to my saved trials
Simvastatin in Aneurysmal Subarachnoid Haemorrhage (STASH) a Multicentre Randomised Controlled Clinical Trial
Simvastatin in Aneurysmal Subarachnoid Haemorrhage (STASH) a Multicentre Randomised Controlled Clinical Trial
Status: Enrolling
Updated:  6/24/2014
Mayo Clinic
675
mi
from 43215
Jacksonville, FL
Simvastatin in Aneurysmal Subarachnoid Haemorrhage (STASH) a Multicentre Randomised Controlled Clinical Trial
Simvastatin in Aneurysmal Subarachnoid Haemorrhage (STASH) a Multicentre Randomised Controlled Clinical Trial
Status: Enrolling
Updated: 6/24/2014
Mayo Clinic
675
mi
from 43215
Jacksonville, FL
Click here to add this to my saved trials
Variability of Molecular Biomarkers and Clinical Measures in People With Myotonic Dystrophy Type 1
A Multicenter Observational Study to Assess the Variability of Molecular Biomarkers and Clinical Measures in Patients With Myotonic Dystrophy Type 1
Status: Enrolling
Updated:  6/24/2014
National Institutes of Health Clinical Center
322
mi
from 43215
Bethesda, MD
Variability of Molecular Biomarkers and Clinical Measures in People With Myotonic Dystrophy Type 1
A Multicenter Observational Study to Assess the Variability of Molecular Biomarkers and Clinical Measures in Patients With Myotonic Dystrophy Type 1
Status: Enrolling
Updated: 6/24/2014
National Institutes of Health Clinical Center
322
mi
from 43215
Bethesda, MD
Click here to add this to my saved trials
Pilot Study to Evaluate MR-guided Laser Ablation of Focal Lesions in Patients With Medically Refractory Partial Epilepsy
A Pilot Study to Evaluate MR-guided Laser Ablation of Focal Lesions in Patients With Medically Refractory Partial Epilepsy
Status: Enrolling
Updated:  6/30/2014
Mayo Clinic Florida
674
mi
from 43215
Jacksonville, FL
Pilot Study to Evaluate MR-guided Laser Ablation of Focal Lesions in Patients With Medically Refractory Partial Epilepsy
A Pilot Study to Evaluate MR-guided Laser Ablation of Focal Lesions in Patients With Medically Refractory Partial Epilepsy
Status: Enrolling
Updated: 6/30/2014
Mayo Clinic Florida
674
mi
from 43215
Jacksonville, FL
Click here to add this to my saved trials
Pilot Study to Evaluate MR-guided Laser Ablation of Focal Lesions in Patients With Medically Refractory Partial Epilepsy
A Pilot Study to Evaluate MR-guided Laser Ablation of Focal Lesions in Patients With Medically Refractory Partial Epilepsy
Status: Enrolling
Updated:  6/30/2014
Mayo Clinic Rochester
559
mi
from 43215
Rochester, MN
Pilot Study to Evaluate MR-guided Laser Ablation of Focal Lesions in Patients With Medically Refractory Partial Epilepsy
A Pilot Study to Evaluate MR-guided Laser Ablation of Focal Lesions in Patients With Medically Refractory Partial Epilepsy
Status: Enrolling
Updated: 6/30/2014
Mayo Clinic Rochester
559
mi
from 43215
Rochester, MN
Click here to add this to my saved trials
Improving Outcomes After Traumatic Injury: A Goal Management Approach
Status: Enrolling
Updated:  7/2/2014
Vanderbilt University Medical Center
333
mi
from 43215
Nashville, TN
Improving Outcomes After Traumatic Injury: A Goal Management Approach
Status: Enrolling
Updated: 7/2/2014
Vanderbilt University Medical Center
333
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
Identification of Diagnostic And Prognostic Biomarkers From Amyotrophic Lateral Sclerosis (ALS) Skin and Adipose Samples
Identification of Diagnostic and Prognostic Biomarkers From Amyotrophic Lateral Sclerosis (ALS) Skin and Adipose Samples
Status: Enrolling
Updated:  7/2/2014
Carolinas Medical Center - Dept of Neurology
350
mi
from 43215
Charlotte, NC
Identification of Diagnostic And Prognostic Biomarkers From Amyotrophic Lateral Sclerosis (ALS) Skin and Adipose Samples
Identification of Diagnostic and Prognostic Biomarkers From Amyotrophic Lateral Sclerosis (ALS) Skin and Adipose Samples
Status: Enrolling
Updated: 7/2/2014
Carolinas Medical Center - Dept of Neurology
350
mi
from 43215
Charlotte, NC
Click here to add this to my saved trials
Establishment of Phenotypic Profiles of Muscular Dystrophies for Understanding Disease Progression, Diagnosis and Development of New Therapies
Status: Enrolling
Updated:  7/2/2014
Carolinas Medical Center - Dept of Neurology
350
mi
from 43215
Charlotte, NC
Establishment of Phenotypic Profiles of Muscular Dystrophies for Understanding Disease Progression, Diagnosis and Development of New Therapies
Status: Enrolling
Updated: 7/2/2014
Carolinas Medical Center - Dept of Neurology
350
mi
from 43215
Charlotte, NC
Click here to add this to my saved trials
Establishment of a Tissue Bank (Blood, CSF) for the Understanding of the Disease Progression and Early Diagnosis of Motor Neuron Disease (MND)
Establishment of a Tissue Bank (Blood, CSF) for the Understanding of the Disease Progression and Early Diagnosis of Motor Neuron Disease (MND).
Status: Enrolling
Updated:  7/2/2014
Carolinas Medical Center - Dept of Neurology
350
mi
from 43215
Charlotte, NC
Establishment of a Tissue Bank (Blood, CSF) for the Understanding of the Disease Progression and Early Diagnosis of Motor Neuron Disease (MND)
Establishment of a Tissue Bank (Blood, CSF) for the Understanding of the Disease Progression and Early Diagnosis of Motor Neuron Disease (MND).
Status: Enrolling
Updated: 7/2/2014
Carolinas Medical Center - Dept of Neurology
350
mi
from 43215
Charlotte, NC
Click here to add this to my saved trials
Association of Endothelial Function and Clinical Outcomes in Subjects Admitted to Chest Pain Unit
The Impact of Short- and Long-term Endothelial Function Assessment by Peripheral Arterial Tonometry (PAT) on Clinical Outcome in Subjects Admitted to Chest Pain Unit (CPU)
Status: Enrolling
Updated:  7/6/2014
Mayo Clinic Chest Pain Unit, Emergency Department
559
mi
from 43215
Rochester, MN
Association of Endothelial Function and Clinical Outcomes in Subjects Admitted to Chest Pain Unit
The Impact of Short- and Long-term Endothelial Function Assessment by Peripheral Arterial Tonometry (PAT) on Clinical Outcome in Subjects Admitted to Chest Pain Unit (CPU)
Status: Enrolling
Updated: 7/6/2014
Mayo Clinic Chest Pain Unit, Emergency Department
559
mi
from 43215
Rochester, MN
Click here to add this to my saved trials
Methylphenidate Treatment of Attention Deficits in Epilepsy
Methylphenidate Treatment of Attentional and Cognitive Deficits in Epilepsy
Status: Enrolling
Updated:  7/9/2014
Stanford University
2100
mi
from 43215
Palo Alto, CA
Methylphenidate Treatment of Attention Deficits in Epilepsy
Methylphenidate Treatment of Attentional and Cognitive Deficits in Epilepsy
Status: Enrolling
Updated: 7/9/2014
Stanford University
2100
mi
from 43215
Palo Alto, CA
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of TAK-137 in Adults With Attention-Deficit/Hyperactivity Disorder
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetic Study of Multiple Rising Doses of TAK-137 in Adult Subjects With Attention-Deficit/Hyperactivity Disorder
Status: Enrolling
Updated:  7/15/2014
Clinical Research Facility
431
mi
from 43215
Marlton, NY
Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of TAK-137 in Adults With Attention-Deficit/Hyperactivity Disorder
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetic Study of Multiple Rising Doses of TAK-137 in Adult Subjects With Attention-Deficit/Hyperactivity Disorder
Status: Enrolling
Updated: 7/15/2014
Clinical Research Facility
431
mi
from 43215
Marlton, NY
Click here to add this to my saved trials
Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism
Randomized Double Blind Placebo Controlled Cross-Over Study of Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism
Status: Enrolling
Updated:  7/17/2014
Beth Israel Deaconess Medical Center
643
mi
from 43215
Boston, MA
Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism
Randomized Double Blind Placebo Controlled Cross-Over Study of Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism
Status: Enrolling
Updated: 7/17/2014
Beth Israel Deaconess Medical Center
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Fluoxetine for Motor, Aphasia, and Neglect Recovery After Ischemic Stroke
Pilot RCT of Fluoxetine vs Placebo to Treat Motor, Language and Unilateral Neglect After Ischemic Stroke
Status: Enrolling
Updated:  7/17/2014
Spaulding Rehabilitation Hospital
643
mi
from 43215
Boston, MA
Fluoxetine for Motor, Aphasia, and Neglect Recovery After Ischemic Stroke
Pilot RCT of Fluoxetine vs Placebo to Treat Motor, Language and Unilateral Neglect After Ischemic Stroke
Status: Enrolling
Updated: 7/17/2014
Spaulding Rehabilitation Hospital
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Using Video Modeled Social Stories to Improve Oral Hygiene in Children With Autism Spectrum Disorder
Using Video Modeled Social Stories to Improve Oral Hygiene in Children With Autism
Status: Enrolling
Updated:  7/21/2014
Yale New Haven Hospital Pediatric Dental Center
537
mi
from 43215
New Haven, CT
Using Video Modeled Social Stories to Improve Oral Hygiene in Children With Autism Spectrum Disorder
Using Video Modeled Social Stories to Improve Oral Hygiene in Children With Autism
Status: Enrolling
Updated: 7/21/2014
Yale New Haven Hospital Pediatric Dental Center
537
mi
from 43215
New Haven, CT
Click here to add this to my saved trials
Using Video Modeled Social Stories to Improve Oral Hygiene in Children With Autism Spectrum Disorder
Using Video Modeled Social Stories to Improve Oral Hygiene in Children With Autism
Status: Enrolling
Updated:  7/21/2014
Yale Pediatric Dental Center Suite 403
537
mi
from 43215
New Haven, CT
Using Video Modeled Social Stories to Improve Oral Hygiene in Children With Autism Spectrum Disorder
Using Video Modeled Social Stories to Improve Oral Hygiene in Children With Autism
Status: Enrolling
Updated: 7/21/2014
Yale Pediatric Dental Center Suite 403
537
mi
from 43215
New Haven, CT
Click here to add this to my saved trials
Effects of a Homeopathic Anti-inflammatory Topical Cream on Ulcers and Neuropathy in the Diabetic Foot
A Double Blind Placebo Controlled Pilot Study to Evaluate the Effects of a Homeopathic Anti-inflammatory Topical Cream on the Healing of Wounds That Develop Into Ulcers and Neuropathy in the Diabetic Foot.
Status: Enrolling
Updated:  7/22/2014
Calvary Hospital Wound Care Clinic
486
mi
from 43215
Bronx, NY
Effects of a Homeopathic Anti-inflammatory Topical Cream on Ulcers and Neuropathy in the Diabetic Foot
A Double Blind Placebo Controlled Pilot Study to Evaluate the Effects of a Homeopathic Anti-inflammatory Topical Cream on the Healing of Wounds That Develop Into Ulcers and Neuropathy in the Diabetic Foot.
Status: Enrolling
Updated: 7/22/2014
Calvary Hospital Wound Care Clinic
486
mi
from 43215
Bronx, NY
Click here to add this to my saved trials
A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults
A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral ALKS 8700 in Healthy Adults
Status: Enrolling
Updated:  7/24/2014
Alkermes Study Site
1065
mi
from 43215
Austin, TX
A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults
A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral ALKS 8700 in Healthy Adults
Status: Enrolling
Updated: 7/24/2014
Alkermes Study Site
1065
mi
from 43215
Austin, TX
Click here to add this to my saved trials
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated:  7/31/2014
Clinical Research Facility
513
mi
from 43215
Albany, NY
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated: 7/31/2014
Clinical Research Facility
513
mi
from 43215
Albany, NY
Click here to add this to my saved trials
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated:  7/31/2014
Clinical Research Facility
659
mi
from 43215
Fayetteville, AR
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated: 7/31/2014
Clinical Research Facility
659
mi
from 43215
Fayetteville, AR
Click here to add this to my saved trials
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated:  7/31/2014
Clinical Research Facility
1972
mi
from 43215
Los Angeles, CA
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated: 7/31/2014
Clinical Research Facility
1972
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated:  7/31/2014
Clinical Research Facility
1163
mi
from 43215
Englewood, CO
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated: 7/31/2014
Clinical Research Facility
1163
mi
from 43215
Englewood, CO
Click here to add this to my saved trials
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated:  7/31/2014
Clinical Research Facility
328
mi
from 43215
Washington,
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated: 7/31/2014
Clinical Research Facility
328
mi
from 43215
Washington,
Click here to add this to my saved trials
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated:  7/31/2014
Clinical Research Facility
955
mi
from 43215
Boca Raton, FL
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated: 7/31/2014
Clinical Research Facility
955
mi
from 43215
Boca Raton, FL
Click here to add this to my saved trials
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated:  7/31/2014
Clinical Research Facility
711
mi
from 43215
Gainesville, FL
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated: 7/31/2014
Clinical Research Facility
711
mi
from 43215
Gainesville, FL
Click here to add this to my saved trials
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated:  7/31/2014
Clinical Research Facility
993
mi
from 43215
Miami, FL
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated: 7/31/2014
Clinical Research Facility
993
mi
from 43215
Miami, FL
Click here to add this to my saved trials
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated:  7/31/2014
Clinical Research Facility
436
mi
from 43215
Atlanta, GA
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated: 7/31/2014
Clinical Research Facility
436
mi
from 43215
Atlanta, GA
Click here to add this to my saved trials
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated:  7/31/2014
Clinical Research Facility
166
mi
from 43215
Indianapolis, IN
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated: 7/31/2014
Clinical Research Facility
166
mi
from 43215
Indianapolis, IN
Click here to add this to my saved trials
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated:  7/31/2014
Clinical Research Facility
460
mi
from 43215
Iowa City, IA
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated: 7/31/2014
Clinical Research Facility
460
mi
from 43215
Iowa City, IA
Click here to add this to my saved trials
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated:  7/31/2014
Clinical Research Facility
620
mi
from 43215
Kansas City, KA
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated: 7/31/2014
Clinical Research Facility
620
mi
from 43215
Kansas City, KA
Click here to add this to my saved trials
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated:  7/31/2014
Clinical Research Facility
784
mi
from 43215
Wichita, KA
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated: 7/31/2014
Clinical Research Facility
784
mi
from 43215
Wichita, KA
Click here to add this to my saved trials
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated:  7/31/2014
Clinical Research Facility
188
mi
from 43215
Louisville, KY
First Time Use of SD-809 in Huntington Disease
A Randomized Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Status: Enrolling
Updated: 7/31/2014
Clinical Research Facility
188
mi
from 43215
Louisville, KY
Click here to add this to my saved trials